StockLens
StockLens
HSIC

Henry Schein (HSIC): Profit Growth Outpaces Sales

Editorial cover illustration for "Henry Schein (HSIC): Profit Growth Outpaces Sales", using clean modern laboratory architecture to interpret its central idea.

By StockLens

August 13, 2026

3 min read

A synthesis of StockLens's multi-domain algorithmic analysis.

82

/100Solid
HSIC

Henry Schein, Inc.

Source as of August 13, 2026

Core Tension

Tempered factor

Current Ratio: Neither strong operating cash flow to current liabilities nor strong quick ratio detected

Tempered factor

Equity Dilution: Mitigated: Justified dilution: Positive Free Cash Flow Growth AND Share Count Growth < 10%

Tempered factor

Interest Coverage: Mitigated: Strong cash interest service: operating cash flow covers interest expense more than an adjustment with positive free cash flow

Tempered factor

Altman Z-Score: No rule defined for this metric

Domain Read

Fundamental
79
Constructive domain signal
Technical
85
Exceptional domain signal
Risk
86
Exceptional domain signal
Sentiment
81
Constructive domain signal
Macro
86
Exceptional domain signal

Strengths

Risk

Constructive enough to anchor part of the thesis.

Macro

Constructive enough to anchor part of the thesis.

Challenges

Fundamental

Less dominant than the leading domains, so it tempers the roll-up.

Sentiment

Less dominant than the leading domains, so it tempers the roll-up.

Uncertainty

Sentiment carries lower confidence than the headline read.

Key Takeaways

  • Henry Schein’s second-quarter non-GAAP diluted EPS and adjusted EBITDA grew 15.5% and 12.7%, respectively, ahead of 6.7% sales growth, prompting management to raise 2026 guidance.
  • Subdued dental capital-equipment demand and projected Forward Revenue Growth (Est.) of 3.7% demonstrate that top-line expansion remains modest.
  • Reaching the targeted US$125 million operational cost-savings exit run-rate by year-end 2026 while maintaining internal sales growth represents the critical test for earnings durability.

Specialty Demand and Margins Lift Outlook

On August 4, 2026, Henry Schein (HSIC) raised its full-year outlook after second-quarter adjusted EBITDA and non-GAAP diluted EPS grew faster than sales. For the Healthcare sector distributor, the improvement is margin-led and selective rather than evidence of a broad demand recovery, particularly while dental capital-equipment demand remains subdued.

Second-quarter net sales reached US$3.46 billion, up 6.7% year over year, supported by internal local-currency sales growth of 4.6%. Non-GAAP diluted EPS grew 15.5% and adjusted EBITDA increased 12.7%. Specialty and technology sales grew 8.7% and 8.2%, respectively, concentrating operational strength away from large dental equipment.

Management raised 2026 sales-growth guidance to 4.5% to 5.5%, lifted non-GAAP diluted EPS guidance to US$5.29 to US$5.39, and increased adjusted EBITDA growth guidance to the mid-to-high single digits. This mix keeps margin expansion, specialty demand, and cost discipline central rather than signaling broad volume expansion.

StockLens calibrated score profile for Henry Schein, Inc. (HSIC): Composite 82, Fundamental 79, Technical 85, Risk 86, Sentiment 81, Macro 86 (0 to 100).StockLens Score Profile:Henry Schein, Inc. (HSIC)0255075100Composite82Fundamental79Technical85Risk86Sentiment81Macro86
StockLens's calibrated composite and per-domain scores for Henry Schein, Inc. (HSIC).

The Rebound Still Depends on Execution

Per StockLens's model, as of August 13, 2026, Henry Schein receives a Composite score of 82 and a Solid rating. The roll-up confirms underlying operational progress, while a Profitability score of 85 and a Growth score of 65 frame the core operational divide.

Underlying factor evidence highlights a Gross Margin of 30.3%, expanded by 1.0 percentage point year over year, alongside cash-backed earnings quality. Projected Forward EPS Growth (Est.) stands at 63.7%, contrasted against Forward Revenue Growth (Est.) of 3.7%. Because three-year net income growth per share is negative 22.5%, the projected profit acceleration follows a prolonged multi-year contraction.

Inventory Turnover sits in the lower half of industry peers, representing an operational counterweight for a distributor. Management is targeting a US$125 million operational cost-savings exit run-rate by year-end 2026. On July 30, 2026, Henry Schein restructured its executive team and integrated its global supply chain operations with global distribution, with three senior leaders moving to advisory roles on October 30, 2026. This reorganization must deliver promised cost reductions without impairing distribution execution.

How the Same Evidence Re-Weights

Across evidence windows and analytical focuses, the table re-weights the same analysis rather than introducing new company evidence.

How StockLens's analysis of Henry Schein, Inc. (HSIC) reads across 9 evidence-history/analysis-focus lenses as display-safe re-weighted approximations.Across Every Investor Lens:Henry Schein, Inc. (HSIC)DefensiveBalancedGrowthShort-term838282Medium-term848382Long-term838281
How the same analysis of Henry Schein, Inc. (HSIC) reads across evidence-history bands and analysis-focus presets.
Show the underlying values
Horizon Focus Composite Score Grade
Short-term (2 wks) Defensive 83 Bullish
Short-term (2 wks) Balanced 82 Bullish
Short-term (2 wks) Growth 82 Bullish
Medium-term (1 mo) Defensive 84 Bullish
Medium-term (1 mo) Balanced 83 Bullish
Medium-term (1 mo) Growth 82 Bullish
Long-term (1 yr) Defensive 83 Bullish
Long-term (1 yr) Balanced 82 Bullish
Long-term (1 yr) Growth 81 Bullish

Display-safe approximation: each cell re-weights the same calibrated per-domain scores by that evidence-history/analysis-focus profile's composite weights. It re-combines published domain scores; it is not a re-run of the engine. Treat each composite as directional, not precise, and not as a personalized suitability assessment or forecast.

What Changes the View

The margin-led interpretation should be monitored against three company-level checks.

  • At year-end 2026, compare the operational cost-savings exit run-rate with management’s US$125 million target; a shortfall would weaken the margin-led interpretation.
  • In subsequent results, watch whether internal sales growth and specialty and technology momentum persist without a recovery in large dental equipment.
  • After the October 30, 2026 leadership and supply-chain transition, track Gross Margin and Inventory Turnover for signs that margin gains are surviving without weaker distribution execution.

How StockLens scores: every company is scored by the same quantitative engine across five domains (Fundamental, Technical, Risk, Sentiment, Macro), combined into one composite and read through the archetype lens that fits its business model. When the engine sets a metric aside, that abstention is deliberate rigor, not missing analysis.

This is not investment advice; it is an algorithmically generated analysis produced by StockLens's quantitative and agentic AI models.

Sources

Scores and grades reflect StockLens's proprietary model, as of August 13, 2026. External facts referenced above are grounded in the following public sources.

  1. businesswire.com
  2. investing.com
  3. perplexity.ai
  4. marketbeat.com
  5. tipranks.com
  6. henryschein.com
  7. nasdaq.com
  8. quartr.com
  9. dentsplysirona.com
  10. tradingview.com
  11. titanwebagency.com
  12. dentaleconomics.com

Tags

HSIC
Healthcare
Medical - Distribution
Deep Dive

Related articles

Editorial cover illustration for "Cronos Group (CRON): Israel Lifts Margin, Probe Threatens Gain", using clean modern laboratory architecture to interpret its central idea.
CRON.TO

Cronos Group (CRON): Israel Lifts Margin, Probe Threatens Gain

On August 5, 2026, Israel's Trade Levies Commissioner notified Cronos Group Inc. (CRON) of a renewed anti-dumping investigation into Canadian cannabis exporters. The notice arrived one day before Cronos reported record Q2 net revenue and a wider gross margin that management linked to a sales-mix shift toward Israel, placing the durability of that operating gain under immediate scrutiny.

3 days ago
Editorial cover illustration for "Envista (NVST): Margin Gains Lift Guidance More Than Sales", using clean modern laboratory architecture to interpret its central idea.
NVST

Envista (NVST): Margin Gains Lift Guidance More Than Sales

On August 5, 2026, dental supplier Envista Holdings (NVST) raised its full-year outlook after second-quarter core sales grew 5.0% and adjusted EBITDA margin expanded 230 basis points to 14.7%. The guidance revision reflects operating efficiency gains rather than broad top-line acceleration. Envista's updated full-year 2026 guidance highlights that operational split: core-sales growth of 3.5% to 4.5% contrasts with adjusted EBITDA growth of 11% to 14% and adjusted EPS of US$1.50 to US$1.55.

3 days ago
Editorial cover illustration for "Protagonist (PTGX): US$192.4M Fee Drove Most Q2 Revenue", using clean modern laboratory architecture to interpret its central idea.
PTGX

Protagonist (PTGX): US$192.4M Fee Drove Most Q2 Revenue

On August 5, 2026, biotechnology developer Protagonist Therapeutics, Inc. (NASDAQ: PTGX) reported second-quarter revenue of US$213.47 million, but US$192.4 million of that top line originated from a single opt-out fee paid by partner Takeda. While a balance sheet anchored by US$849.5 million in cash, cash equivalents, and marketable securities provides substantial liquidity, the concentration of revenue in nonrecurring deal cash leaves the firm's ongoing commercial earnings capacity unproven.

Aug 6, 2026
Back to Articles